Efficacy of baricitinib in patients with moderate-to-severe rheumatoid arthritis up to 6.5 years of treatment: results of a long-term study
Authors' conclusion
Treatment with baricitinib 4 mg or 2 mg demonstrated efficacy up to 6.5 years with maintained LDA/remission results across SDAI, CDAI and DAS28-hsCRP consistent with previously reported data, and was well tolerated.
Study context
- Population
- Patients with active RA with inadequate response to MTX, csDMARDs or bDMARDs, treated with once-daily baricitinib 4 mg or 2 mg
- Comparison
- MTX-IR vs csDMARD-IR vs bDMARD-IR
- Outcome
- Main outcomes: Low disease activity (LDA) (Simplified Disease Activity Index (SDAI) ≤11), clinical remission (SDAI ≤3.3) and physical function (Health Assessment Questionnaire Disability Index (HAQ-DI) ≤0.5)
- Follow-up
- Week 340 or 336
Methodological detailspooled data from three completed phase III studies and one completed long-term extension study, completer and non-responder imputation (NRI) analyses
- Pooled data from three completed phase III studies and one completed long-term extension study
- Completer and NRI analyses
Main finding
As reported in the abstract
LDA (SDAI ≤11), baricitinib 4 mg, NRI/completer
MTX-IR
37%/83%
csDMARD-IR
35%/83%
bDMARD-IR
23%/73%
Further findings
| Outcome | MTX-IR | csDMARD-IR | bDMARD-IR |
|---|---|---|---|
| Main outcome: remission (SDAI ≤3.3), baricitinib 4 mg, NRI/completer · week 340 or 336NRI/completer analyses | 20%/40% | 13%/32% | 9%/30% |
| Main outcome: HAQ-DI ≤0.5, baricitinib 4 mg, NRI/completer · week 340 or 336NRI/completer analyses | 31%/51% | 25%/46% | 24%/38% |
Original publication
Efficacy of baricitinib in patients with moderate-to-severe rheumatoid arthritis up to 6.5 years of treatment: results of a long-term study. Rheumatology (Oxford). Published 22 January 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →